GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Cyfuse Biomedical KK 4892.T · JPY

Health Care · Tokyo Stock Exchange · 🇯🇵 Japan

Compare

514

+2.80%

Close of 9 Nov 2026, in JPY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in JPY, from our data supplier.

FY2025

Revenue

¥231.0m

FY2020FY2025

Net income

−¥763.8m

FY2020FY2025

Free cash flow

−¥581.9m

FY2020FY2025

Shareholders' equity

¥2.76bn

FY2020FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020
Revenue¥231.0m¥54.4m¥61.1m¥374.5m¥708.2m¥137.5m
Gross profit¥78.4m¥1.6m−¥378,000¥223.9m¥568.2m¥63.8m
Research and development—¥469.6m¥375.6m¥303.7m¥266.5m¥242.6m
Operating income−¥828.2m−¥896.1m−¥697.4m−¥427.7m¥70.6m−¥372.1m
Net income−¥763.8m−¥872.2m−¥589.2m−¥474.0m¥142.9m−¥329.5m
Diluted earnings per share-72.91-107.16-75.28-60.9714.20-32.73

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Total assets¥4.27bn¥3.52bn¥4.21bn¥4.82bn¥2.65bn¥2.20bn
Cash and short-term investments¥3.73bn¥3.05bn¥3.87bn¥4.44bn¥2.41bn¥2.07bn
Total liabilities¥1.51bn¥975.6m¥1.01bn¥1.05bn¥746.1m¥646.8m
Debt¥1.31bn¥852.8m¥913.0m¥857.8m¥569.1m¥529.5m
Shareholders' equity¥2.76bn¥2.54bn¥3.20bn¥3.77bn¥1.90bn¥1.55bn
Shares outstanding10m8m8m8m10m10m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations−¥534.8m−¥760.6m−¥562.3m−¥403.6m¥161.5m−¥294.0m
Capital spending−¥47.1m−¥7.6m−¥19.5m−¥228.3m—−¥264,000
Free cash flow−¥581.9m−¥768.2m−¥581.8m−¥631.9m¥161.5m−¥294.3m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue¥75.8m¥28.5m¥169.0m¥32.5m¥5.2m¥24.2m¥28.1m¥8.3m
Gross profit¥44.7m¥20.1m¥79.0m¥1.5m−¥8.1m¥13.7m¥1.2m−¥10.1m
Operating income−¥201.6m−¥215.9m−¥138.2m−¥218.7m−¥230.9m−¥240.3m−¥221.3m−¥225.8m
Net income−¥210.4m−¥224.1m−¥126.7m−¥234.7m−¥239.5m−¥163.0m−¥208.1m−¥217.0m
Diluted earnings per share-20.90-22.27-12.09-22.40-22.86-15.56-25.56-26.66
Total assets¥3.93bn¥4.09bn¥4.27bn¥4.30bn¥3.23bn¥3.36bn¥3.52bn¥3.66bn
Cash and short-term investments¥3.39bn¥3.53bn¥3.73bn¥3.74bn¥2.70bn¥2.83bn¥3.05bn¥3.19bn
Debt¥1.23bn¥724.7m¥1.31bn¥474.7m¥766.0m¥498.0m¥525.8m¥468.0m
Shareholders' equity¥2.62bn¥2.75bn¥2.76bn¥2.86bn¥2.33bn¥2.39bn¥2.54bn¥2.73bn

Financial ratios

Data as of 11 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin33.9%2.9%-0.6%59.8%80.2%46.4%
Operating margin-358.5%-1645.9%-1141.2%-113.5%10.0%-270.7%
Net margin-330.7%-1602.0%-964.1%-126.6%20.2%-239.7%
Return on equity-27.7%-34.3%-18.4%-12.6%7.5%-21.3%
Return on assets-17.9%-24.8%-14.0%-9.8%5.4%-15.0%
Free cash flow yield-7.5%-14.9%-11.2%-3.6%——
Revenue growth324.3%-10.9%-83.7%-47.1%415.1%—
Earnings growth-12.4%48.0%24.3%-431.7%-143.4%—
Current ratio4.54x5.00x5.98x6.69x6.62x10.41x
Debt to equity0.48x0.34x0.29x0.23x0.30x0.34x
Equity ratio64.6%72.3%76.0%78.3%71.8%70.6%
Interest coverage-58.00x-94.19x-71.36x-57.01x13.48x-62.71x
R&D as a share of sales—862.4%614.6%81.1%37.6%176.5%
Buybacks as a share of market value-28.7%-4.0%-0.7%———

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-14.9%10.9%—
Operating income24.6%17.4%—
Net income17.2%18.3%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin28.0%42.1%59.7%—
Operating margin-604.1%-395.2%-201.1%—
Net margin-573.2%-374.4%-184.2%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022
Price to earnings-8.1-4.2-10.1-21.3
Price to sales26.867.697.627.0

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.